Journal
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
Volume 122, Issue -, Pages 3-13Publisher
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.semcdb.2021.05.019
Keywords
Cardiac reprogramming; Cardiac regeneration; Somatic cell reprogramming
Categories
Funding
- NIH [HL130253, HL-138426, HD-087351]
- Foundation Leducq Transatlantic Networks of Excellence in Cardiovascular Research
- Robert A. Welch Foundation [1-0025]
- NIH T32 Training grant [5T32HL125247-04]
Ask authors/readers for more resources
Ischemic heart disease is the leading cause of morbidity and mortality worldwide, and finding new ways to promote cardiomyocyte regeneration is crucial. Direct reprogramming of cardiac fibroblasts into induced cardiac-like myocytes (iCMs) has shown promising potential, but there are challenges in reprogramming adult human fibroblasts.
Ischemic heart disease is the leading cause of morbidity, mortality, and healthcare expenditure worldwide due to an inability of the heart to regenerate following injury. Thus, novel heart failure therapies aimed at promoting cardiomyocyte regeneration are desperately needed. In recent years, direct reprogramming of resident cardiac fibroblasts to induced cardiac-like myocytes (iCMs) has emerged as a promising therapeutic strategy to repurpose the fibrotic response of the injured heart toward a functional myocardium. Direct cardiac reprogramming was initially achieved through the overexpression of the transcription factors (TFs) Gata4, Mef2c, and Tbx5 (GMT). However, this combination of TFs and other subsequent cocktails demonstrated limited success in reprogramming adult human and mouse fibroblasts, constraining the clinical translation of this therapy. Over the past decade, significant effort has been dedicated to optimizing reprogramming cocktails comprised of cardiac TFs, epigenetic factors, microRNAs, or small molecules to yield efficient cardiac cell fate conversion. Yet, efficient reprogramming of adult human fibroblasts remains a significant challenge. Underlying mechanisms identified to accelerate this process have been centered on epigenetic remodeling at cardiac gene regulatory regions. Further studies to achieve a refined understanding and directed means of overcoming epigenetic barriers are merited to more rapidly translate these promising therapies to the clinic.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available